Dr. Michael Naughton

Psychiatry
Cedar Hills Hospital
10300 SW Eastridge St, 
Portland, OR 
Clinical Trials:Currently Recruiting for 1 Trial
Cedar Hills Hospital
10300 SW Eastridge St, 
Portland, OR 

Overview

Michael Naughton is a Psychiatrist practicing medicine in Portland, Oregon.

His clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, HER2 Negative Breast Cancer, Bipolar Disorder (BPD), and Schizophrenia.

He is actively involved in clinical research, co-authoring 64 peer reviewed articles and participating in 23 clinical trials.

Specialties

Psychiatry

Licenses

Psychiatry & Neurology in OR

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

BridgeSpan
  • EPO
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

Cedar Hills Hospital
10300 SW Eastridge St, Portland, OR 97225
Other Locations
Office
825 Fairfax Ave Ste 710, Norfolk, VA 23507

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Enrollment Status: Recruiting
Publish Date: July 28, 2025
Intervention Type: Drug, Behavioral, Other
Study Drugs: Goserelin, Anastrozole, Exemestane, Fulvestrant, Tamoxifen
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: August 20, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
Enrollment Status: Terminated
Publish Date: November 07, 2022
Intervention Type: Drug, Procedure
Study Drugs: Docetaxel, Carboplatin
Study Phase: Phase 2
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
Enrollment Status: Terminated
Publish Date: November 01, 2022
Intervention Type: Drug, Biological
Study Drugs: Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil
Study Phase: Phase 2
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Procedure, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

64 Total Publications

Transmission anomalies in 2D photonic crystals from the checkerboard family: from broken to hidden symmetries and plasmon "spoofing".
Transmission anomalies in 2D photonic crystals from the checkerboard family: from broken to hidden symmetries and plasmon "spoofing".
Journal: Optics express
Published: June 14, 2025
Similar Doctors
Expertise in
5
conditions
Dr. Todd Palumbo
Psychiatry
Expertise in
5
conditions
Dr. Todd Palumbo
Psychiatry
Referral may be required

Cedar Hills Hospital

10300 SW Eastridge St, 
Portland, OR 
 (2453.3 miles away)
503-944-5000
Languages Spoken:
English
See accepted insurances

Todd Palumbo is a Psychiatrist practicing medicine in Portland, Oregon. Dr. Palumbo is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Bipolar Disorder (BPD), Schizoaffective Disorder, Seasonal Affective Disorder (SAD), and Schizophrenia.

Expertise in
6
conditions
Expertise in
6
conditions
Referral may be required

Ubh Of Oregon LLC

10300 Sw Eastridge St, 
Portland, OR 
 (2453.3 miles away)
503-944-5000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Brian Esparza is a Psychiatrist practicing medicine in Portland, Oregon. Dr. Esparza is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Bipolar Disorder (BPD), Opioid Use Disorder, Schizoaffective Disorder, and Seasonal Affective Disorder (SAD). Dr. Esparza is currently accepting new patients.

Expertise in
1
conditions
Dr. Joshua R. Leibovitz
Psychiatry | Emergency Medicine
Expertise in
1
conditions
Dr. Joshua R. Leibovitz
Psychiatry | Emergency Medicine
Referral may be required
2600 Se Belmont St, 
Portland, OR 
 (2446.3 miles away)
503-475-2844
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Joshua Leibovitz is a Psychiatrist and an Emergency Medicine provider practicing medicine in Portland, Oregon. Dr. Leibovitz is highly rated in 1 condition, according to our data. His clinical expertise encompasses Opioid Use Disorder. Dr. Leibovitz is currently accepting new patients.

Frequently Asked Questions about Dr. Michael Naughton

How do I make an appointment with Dr. Michael Naughton?

You can book an appointment with Dr. Michael Naughton by calling their office at 503-944-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael Naughton a top-rated expert for PIK3CA-Related Overgrowth Spectrum?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael Naughton is classified as an Experienced expert for PIK3CA-Related Overgrowth Spectrum, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael Naughton specialize in?

While Dr. Michael Naughton is a Psychiatry, they have specific expertise in PIK3CA-Related Overgrowth Spectrum, HER2 Negative Breast Cancer, and Bipolar Disorder (BPD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Psychiatry.

Does Dr. Michael Naughton participate in research or clinical trials?

Yes. Dr. Michael Naughton has published 64 articles and abstracts on conditions like PIK3CA-Related Overgrowth Spectrum. You can view a list of Dr. Michael Naughton's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael Naughton accept my insurance?

Dr. Michael Naughton accepts most major insurance plans, including BridgeSpan and Medicaid. We recommend calling the office directly at 503-944-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Naughton's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile